• Data to be presented at EADV 2019 will further confirm the durability of CIMZIA® (certolizumab pegol) treatment in moderate-to-severe plaque psoriasis, including new three-year efficacy data • New positive 60-week outcomes data from Phase 2 studies underscore the potential of bimekizumab to improve scalp and nail psoriasis and health-related quality of life in psoriasis patients • In total, UCB will present nine abstracts at the meeting, demonstrating the company’s ongoing commitment to improving the lives of people with psoriasis and psoriatic arthritis
Brussels, Belgium – 9 October 2019 – UCB, a global biopharmaceutical company, today announced new data on the use of the Fc-free anti-TNF treatment, CIMZIA® (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) will be presented at the 28th European Academy of Dermatology and Venereology congress (EADV) in Madrid, October 9-13, 2019. Data include three-year outcomes in psoriasis and four-year results in PsA from the open-label extension studies of CIMZIA.2 Additionally, the company will share 60-week results from the Phase 2 clinical development program of the company’s pipeline molecule bimekizumab – a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F cytokines, thought to be key drivers of psoriasis.
“Results presented at EADV 2019 will reinforce and support the durability profile of CIMZIA efficacy in the treatment of both psoriasis and psoriatic arthritis, and provide further evidence as to the exciting potential of bimekizumab in psoriasis,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President, Immunology Patient Value Unit, UCB. “Patients with psoriasis deserve rapid and sustainable treatment results. The data we will share in Madrid show our commitment to delivering against these key patient needs.”
Reflecting UCB’s efforts to better understand the impact of psoriasis on patients, and the unique needs of women, UCB will present new results from a sample of almost 90,000 respondents of the World Psoriasis Happiness Surveys. These findings highlight gender as a strong predictor of psychological and social well-being in people living with psoriasis and PsA, more so than geographies. The analysis illustrates how psoriasis and PsA can negatively affect women more than men when it comes to life satisfaction, loneliness, mood and self-esteem. Worse life satisfaction, stress, loneliness and isolation were felt most in young women with psoriasis.
New CIMZIA three-year efficacy data in plaque psoriasis from a pooled analysis of the completed CIMPASI-1 and CIMPASI-2 open-label extension Phase 3 studies will be presented as an oral presentation at EADV 2019; CIMZIA’s safety profile remains consistent with previously reported data. Additional pooled results from these trials include CIMZIA 48-week sustained efficacy data in psoriasis of the head and neck, areas where disease manifestations can cause high degrees of emotional distress, particularly for female patients. A post-hoc analysis of the four-year RAPID-PsA study will also be highlighted, showing durability of response of CIMZIA in PsA. The ongoing focus on researching the long-term efficacy and safety of CIMZIA demonstrates how UCB continues its ongoing commitment to improving the lives of people with psoriasis.
New 60-week data on novel investigational molecule bimekizumab, from the BE ABLE Phase 2 clinical development program, will be shared in an oral presentation. The findings show rapid and sustained improvements in quality of life (as measured by the Dermatology Life Quality Index), which positively associate with clinical outcomes in patients with moderate-to-severe plaque psoriasis. Positive scalp and nail disease outcomes at 60 weeks will also be presented, further supporting bimekizumab’s potential.
The safety and efficacy of bimekizumab have not been established, and it is not approved by any regulatory authority worldwide.